scispace - formally typeset
K

Katherine P. Rankin

Researcher at University of California, San Francisco

Publications -  212
Citations -  21238

Katherine P. Rankin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Frontotemporal dementia & Dementia. The author has an hindex of 54, co-authored 169 publications receiving 16202 citations. Previous affiliations of Katherine P. Rankin include National and Kapodistrian University of Athens & University of Western Ontario.

Papers
More filters

The Interpersonal Reactivity Index (IRI) scale in Greek patients with dementia.

TL;DR: Interpersonal Reactivity Index scale (IRI) is a cross-cultural useful tool for immediate neuropsychological examination regarding the evaluation of empathy in patients with different types of dementia and different patterns of anatomical lesions show a reduction in distinct aspects of empathy.
Journal ArticleDOI

Computationally derived anatomic subtypes of behavioral variant frontotemporal dementia show temporal stability and divergent patterns of longitudinal atrophy.

TL;DR: Ranasinghe et al. as mentioned in this paper investigated the longitudinal stability of the four previously identified anatomic subtypes in 72 bvFTD patients and applied a voxel-wise mixed effects model to examine subtype differences in atrophy patterns across multiple timepoints.
Journal Article

Validation of the Dynamic Affect Recognition Test (DART): Behavior and Anatomy in Neurodegenerative Disease (P6.237)

TL;DR: A quick, tablet-based, video test of emotion reading that matches the expected structural anatomy of emotion, on which diagnostic groups known for socioemotional deficits fail, while those with intact real-life emotion reading perform normally despite cognitive deficits is developed.
Journal ArticleDOI

Determinants of survival in autopsy-confirmed patients with behavioral variant frontotemporal dementia (bvFTD): Second Report of the international bvFTD criteria consortium (FTDC)

TL;DR: It is suggested that Dimebon has mitochondrial actions that could play a role in modulating cell processes involving protein turnover which in the setting of neurodegenerative proteinopathies may be beneficial.
Journal Article

Clinical Characteristics of bvFTD Across CDR Stages (P3.201)

TL;DR: This cross-sectional analysis suggests that several domains beyond those included in bvFTD criteria may be present early and progress throughout the disease.